NOT FOR REPRINT
Page Printed from: benefitspro.com/author/profile/caroline-chen-anna-edney
Sign In To follow
The FDA hopes to learn more about drug side effects from data on a patient network called PatientsLikeMe.
23andMe Inc., the genetic-testing company backed by Google Inc., gained U.S. regulatory permission to sell consumers its first screening kit to detect whether they carry the risk of a rare genetic disorder.